Woman with child

Prenatal MaterniT Genome

A fully validated genome-wide NIPS (NIPT)

The only clinically validated genome-wide NIPS (NIPT), screens all 23 chromosome pairs, reporting aneuploidies, large deletions and duplications greater than 7 Mb in addition to select microdeletions.

Offering a breadth of coverage unlike any other NIPS (NIPT) available to date

Like most NIPSs (NIPTs), MaterniT® GENOME screens for common trisomies (such as 21, 18, and 13) and fetal sex. Like some more comprehensive NIPSs (NIPTs), it also screens for sex chromosome aneuploidies, and analyzes seven clinically significant microdeletion regions.

Unlike any other NIPS (NIPT) to date, MaterniT GENOME also analyzes every chromosome and can provide information about clinically relevant microdeletions and gains or losses of chromosome material ≥ 7 Mb across the genome.

By combining increased sequencing depth with industry-leading expertise, the MaterniT GENOME test offers a breadth of coverage unlike any other noninvasive prenatal screening available to date.

Sensitivity and specificity diagram
Genome referral reasons graphic

When should you use MaterniT GENOME tests?

MaterniT GENOME is an ideal fit for high-risk pregnancies where a patient may wish to avoid a diagnostic procedure, or where screening for common aneuploidies may not be enough.

What will you see with the MaterniT GENOME test?

This chart shows a summary of the 453 positive results seen by your peers. To view turnaround times, specimen requirements and other clinical details, view MaterniT GENOME in the test menu.

Risk diagram

MaterniT specimen collection kit

Starting in July 2023, we are updating our MaterniT cfDNA specimen collection kits with a new look to help increase understanding that MaterniT is a screening test. The kit components and specimen collection requirements will not change.

Download Flyer


Additional Resources